Drug Type Monoclonal antibody |
Synonyms CLM-101, NOV 1105, YYB 101 + [1] |
Target |
Mechanism HGF inhibitors(Hepatocyte growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal cancer recurrent | Phase 2 | KR | Cell Lab MedStartup | 09 Aug 2019 |
Metastatic Colorectal Carcinoma | Phase 2 | KR | Cell Lab MedStartup | 09 Aug 2019 |
Colorectal Cancer | Phase 2 | KR | Cell Lab MedStartup | - |
Advanced Malignant Solid Neoplasm | Phase 1 | KR | Cell Lab MedStartup | 13 Jul 2015 |
Ovarian Cancer | Preclinical | KR | Cell Lab MedStartup | 04 Jul 2023 |
Pancreatic Cancer | Preclinical | KR | Cell Lab MedStartup | 04 Jul 2023 |
NCT04368507 (ESMO2023) Manual | Phase 1/2 | Colorectal Cancer Last line | 35 | YYB101+ irinotecan | cawidplobo(zfgsmzkxxq) = khnjlfntgg lixvzuiqiu (mkhyjbstvs ) View more | Positive | 22 Oct 2023 |
Phase 1 | 39 | nybwwbkiut(qsnztwkvnd) = mxwykzpsol onuppsjdqq (zckeunzfgu ) View more | Positive | 02 Jun 2020 | |||
Phase 1 | 39 | knnzmzziug(ilaoykmmuo) = xophgclstv nkpateosbe (bjfhtfzycp ) View more | Positive | 26 May 2019 | |||
Phase 1 | 22 | mvxismzzlt(sdqpdqtppr) = anorexia, ALT increase, azotemia were observed at later dose gpwdwyqxvq (evncycupfq ) | Positive | 01 Jun 2018 |